Efficacy and Safety of Apixaban Thromboprophylaxis According to Baseline Chemotherapy Class in High-Risk Ambulatory Cancer Patients: A Post Hoc Analysis of the AVERT Trial.
Feng NL, Doering J, Wang TF, Mallick R, Le Gal G, Shaw J, Hill D, Shivakumar S, Tagalakis V, Wells P, Carrier M
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.